Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)

NCT04627428 is registered in ClinicalTrials.gov with Luxa Biotechnology, LLC as lead sponsor.

NCT NCT04627428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04627428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase1/2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)
Lead sponsor
Luxa Biotechnology, LLC
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 5, 2022
Completion date
December 1, 2026
Enrollment
18 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dry age-related macular degeneration